Shares of Moderna Inc were up by 4.9% in pre-market trading on Feb. 25 as the biotechnology company announced new capital investments to enable additional production of the COVID-19 vaccine at its manufacturing facilities. Moderna expects the investments to enable it to increase capacity to approximately 1.4 billion doses at 100 µg per dose by 2022. The  capital investments by Moderna (MRNA) will also enable production of potential vaccine booster doses for emerging variants of the SARS-CoV-2 virus. MRNA expects it would probably be a year before additional production capacity is available.